764 related articles for article (PubMed ID: 25297091)
1. Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates.
Forny-Germano L; Lyra e Silva NM; Batista AF; Brito-Moreira J; Gralle M; Boehnke SE; Coe BC; Lablans A; Marques SA; Martinez AM; Klein WL; Houzel JC; Ferreira ST; Munoz DP; De Felice FG
J Neurosci; 2014 Oct; 34(41):13629-43. PubMed ID: 25297091
[TBL] [Abstract][Full Text] [Related]
2. Tau Oligomer-Containing Synapse Elimination by Microglia and Astrocytes in Alzheimer Disease.
Taddei RN; Perbet R; Mate de Gerando A; Wiedmer AE; Sanchez-Mico M; Connors Stewart T; Gaona A; Melloni A; Amaral AC; Duff K; Frosch MP; Gómez-Isla T
JAMA Neurol; 2023 Nov; 80(11):1209-1221. PubMed ID: 37812432
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease like pathology induced six weeks after aggregated amyloid-beta injection in rats: increased oxidative stress and impaired long-term memory with anxiety-like behavior.
Sharma S; Verma S; Kapoor M; Saini A; Nehru B
Neurol Res; 2016 Sep; 38(9):838-50. PubMed ID: 27431920
[TBL] [Abstract][Full Text] [Related]
4. Brains of rhesus monkeys display Aβ deposits and glial pathology while lacking Aβ dimers and other Alzheimer's pathologies.
Zhang J; Chen B; Lu J; Wu Y; Wang S; Yao Z; Zhu L; Qiao Y; Sun Q; Qin W; Zhao Q; Jia J; Wei C
Aging Cell; 2019 Aug; 18(4):e12978. PubMed ID: 31165579
[TBL] [Abstract][Full Text] [Related]
5. The Co-oligomers of Aβ42 and Human Islet Amyloid Polypeptide Exacerbate Neurotoxicity and Alzheimer-like Pathology at Cellular Level.
Deng J; Liu B; Tao Q; Luo Y; Zhu Y; Huang X; Yue F
Neuroscience; 2024 May; 547():37-55. PubMed ID: 38604526
[TBL] [Abstract][Full Text] [Related]
6. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T
Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
[TBL] [Abstract][Full Text] [Related]
7. Synaptic changes in Alzheimer's disease and its models.
Pozueta J; Lefort R; Shelanski ML
Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Effects of Acute Amyloid β Oligomer Exposure in the Rat.
Wong RS; Cechetto DF; Whitehead SN
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563885
[TBL] [Abstract][Full Text] [Related]
10. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid.
Nimmrich V; Ebert U
Rev Neurosci; 2009; 20(1):1-12. PubMed ID: 19526730
[TBL] [Abstract][Full Text] [Related]
11. A Synthetic Pro-Drug Peptide Reverses Amyloid-β-Induced Toxicity in the Rat Model of Alzheimer's Disease.
Kumar S; Srivastav S; Fatima M; Giri RS; Mandal B; Mondal AC
J Alzheimers Dis; 2019; 69(2):499-512. PubMed ID: 30958369
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.
De Felice FG; Wu D; Lambert MP; Fernandez SJ; Velasco PT; Lacor PN; Bigio EH; Jerecic J; Acton PJ; Shughrue PJ; Chen-Dodson E; Kinney GG; Klein WL
Neurobiol Aging; 2008 Sep; 29(9):1334-47. PubMed ID: 17403556
[TBL] [Abstract][Full Text] [Related]
13. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
14. In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches.
Balducci C; Forloni G
Curr Pharm Des; 2014; 20(15):2491-505. PubMed ID: 23859553
[TBL] [Abstract][Full Text] [Related]
15. Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.
Yang T; Li S; Xu H; Walsh DM; Selkoe DJ
J Neurosci; 2017 Jan; 37(1):152-163. PubMed ID: 28053038
[TBL] [Abstract][Full Text] [Related]
16. Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease.
Jeong S
Mol Cells; 2017 Sep; 40(9):613-620. PubMed ID: 28927263
[TBL] [Abstract][Full Text] [Related]
17. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats.
Garabadu D; Verma J
Neurochem Int; 2019 Sep; 128():39-49. PubMed ID: 31004737
[TBL] [Abstract][Full Text] [Related]
19. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.
Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST
J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
